CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial
Year: 2023
Type: conference-abstract
Source: Value in Health
Authors: M. Sekeres, V. Santini, M. Diez-Campelo, R. Komrokji, P. Fenaux, M. Savona, Y. Madanat, D. Valcárcel-Ferreiras, T. Illmer, A. Jonášová, P. Bělohlávková, A. Regnault, K. Creel, N. Sengupta, L. Sherman, T. Berry, S. Dougherty, S. Shah, Q. Xia, L. Sun, Y. Wan, F. Huang, A. Ikin, S. Navada, F. Feller, A. Zeidan, U. Platzbecker
Institutions: University of Miami, Sylvester Comprehensive Cancer Center, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Moffitt Cancer Center, Université Paris Cité, Hôpital Saint-Louis, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Vall d'Hebron Hospital Universitari, University Hospital Hradec Králové, Geron (United States), Yale Cancer Center, Yale University, University Hospital Leipzig
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4390128609